Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug candidate MEAI from attendees at one of the largest annual analytical chemistry conferences in the world Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY)…

Source

Previous articleSmall Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
Next articleSmall Pharma Reports Fiscal Third Quarter 2023 Highlights